Bristol-myers Squibb Compnay

Astrazeneca Ab

Lexicon Pharmaceuticals, Inc.

Astra Aktiebolag

Syngene International Limited

Albany Molecular Research, Inc.

Astra Ab

Bristol Meyers Squibb Company

John E Macor

Carolyn Diane Dzierba

Guanglin Luo

Joanne J Bronson

Gene Michael Dubowchik

Jianliang Shi

Richard Eric Olson

Lorin A Thompson, Iii

Ramesh Kumar Sistla

Dalton King

Ling Chen

Susheel Jethanand Nara

Kenneth M Boy

Guixue Yu

Sreekantha Ratna Kumar

Yingzhi Bi

Ramkumar Rajamani

Vivekananda M Vrudhula

Alaric J Dyckman

Dharmpal S Dodd

Scott Hunter Watterson

Christopher P Mussari

Laxman Pasunoori

Graham S Poindexter

Richard A Hartz

Andrew P Degnan

Lawrence R Marcin

F Christopher Zusi

Saleem Ahmad

William John Pitts

Yong-Jin Wu

Louis John Lombardo

Prasad V Chaturvedula

Ivar M McDonald

Jayakumar Sankara Warrier

Qingjie Liu

Amy C Hart

Xiaojun Han

Trevor C Sherwood

Srinivasan Thangathirupathy

Natesan Murugesan

Shoshana L Posy

Prasanna Sivaprakasam

Satheesh Kesavan Nair

George O Tora

Eifion D Phillips

Junqing Guo

Bireshwar Dasgupta

Yunhui Zhang

Tasir Shamsul Haque

Sing-Yuen Sit

Jie Chen

Michael Frederick Parker

Srinivas Cheruku

Zhengxiang Gu

R Michael Lawrence

Douglas G Batt

Edward H Ruediger

Joseph Anthony Tino

Steven H Spergel

Yulian Zhang

Michael Alan Green

George C Morton

Rejean Ruel

Khehyong Ngu

Timothy F Herpin

Haiquan Fang

Carl P Bergstrom

Soodamani Thangavel

Michael A Poss

John V Duncia

Joseph B Santella

John T Hynes

Ronald J Mattson

Kenneth Gordon Carson

Daniel S Gardner

Cynthia Anne Fink

Giovanni Cianchetta

Hong Wu

David R Tortolani

Kandhasamy Sarkunam

Venkatram Reddy Paidi

Brian K Whiteley

Edwin S Wu

Prasada Rao Jalagam

Shuang Liu

Andrew Charles Good

Peter Guzzo

Bruce Francis Molino

Joseph P Yevich

John L Gilmore

Min Ding

Scott Hunter

Fukang Yang

Harold N Weller, Iii

Samuel Gerritz

Brian Lee Venables

Andrew J Tebben

Stephen E Mercer

Zhizhen Barbara Zheng

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Indazole carboxamides as kinase inhibitors

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Biaryl kinase inhibitors

Disclosed are compounds of Formula (I) or a salt thereof, wherein R, R, R, R, R, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R, R, R, R, R, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole compounds

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; R, R, R, R, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Indole carboxamide compounds

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein. 

Aminoimidazopyridazines as kinase inhibitors

Disclosed are compounds of Formula (I) or a salt thereof, wherein R, R, R, R, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors

Disclosed are compounds of Formula (I): or a salt thereof, wherein Q, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Carbazole derivatives

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

Pyrimidine carboxamides as GSK-3 inhibitors

Growing community of inventors

Guilford, CT, United States of America

John E Macor